1887
Volume 2015, Issue 1
  • ISSN: 2305-7823
  • E-ISSN:

Abstract

In the Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy (PALLAS) study, dronedarone use was associated with an excess risk of stroke, cardiovascular death and hospitalizations. However, an increased level in the serum digoxin level was observed in the dronedarone arm, as it is a potent inhibitor of the P-glycoprotein transport system. The PALLAS subanalysis suggests that digoxin-dronedarone interaction was responsible for the higher arrhythmic death rate observed in the trial. These data are consistent with several other studies that demonstrate the potential hazard of the use of digoxin in heart failure and/or atrial fibrillation. One must consider other safer alternatives before prescribing digoxin in atrial fibrillation patients.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2015.4
2015-03-01
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2015/1/gcsp.2015.4.html?itemId=/content/journals/10.5339/gcsp.2015.4&mimeType=html&fmt=ahah

References

  1. [1]. Zimetbaum   P. . Antiarrhythmic Drug Therapy for Atrial Fibrillation. . Circulation   2012; ;125: 2 : 381– 389 . doi:10.1161/CIRCULATIONAHA.111.019927 .
    [Google Scholar]
  2. [2]. Hohnloser   S., , Crijns   H., , van Eickels   M., , Gaudin   C., , Page   R., , Torp-Pedersen   C., , Connolly   SJ. . Effect of dronedarone on cardiovascular events in atrial fibrillation. . Rev Port Cardiol . 2009; ;28: : 345– 347 .
    [Google Scholar]
  3. [3]. Connolly   SJ., , Camm   AJ., , Halperin   JL., , Joyner   C., , Alings   M., , Amerena   J., , Atar   D., , Avezum   Á., , Blomström   P., , Borggrefe   M., , Budaj   A., , Chen   S-A., , Ching   CK., , Commerford   P., , Dans   A., , Davy   J-M., , Delacrétaz   E., , Di Pasquale   G., , Diaz   R., , Dorian   P., , Flaker   G., , Golitsyn   S., , Gonzalez-Hermosillo   A., , Granger   CB., , Heidbüchel   H., , Kautzner   J., , Kim   JS., , Lanas   F., , Lewis   BS., , Merino   JL., , Morillo   C., , Murin   J., , Narasimhan   C., , Paolasso   E., , Parkhomenko   A., , Peters   NS., , Sim   K-H., , Stiles   MK., , Tanomsup   S., , Toivonen   L., , Tomcsányi   J., , Torp-Pedersen   C., , Tse   H-F., , Vardas   P., , Vinereanu   D., , Xavier   D., , Zhu   J., , Zhu   J-R., , Baret-Cormel   L., , Weinling   E., , Staiger   C., , Yusuf   S., , Chrolavicius   S., , Afzal   R., , Hohnloser   SH. . Dronedarone in High-Risk Permanent Atrial Fibrillation. . N Eng J Med . 2011; ;365: 24 : 2268– 2276 . doi:10.1056/NEJMoa1109867. .
    [Google Scholar]
  4. [4]. Hohnloser   SH., , Halperin   JL., , Camm   AJ., , Gao   P., , Radzik   D., , Connolly   SJ. . Interaction Between Digoxin and Dronedarone in the PALLAS Trial. . 2014; .
    [Google Scholar]
  5. [5]. Singh   BN., , Connolly   SJ., , Crijns   HJGM., , Roy   D., , Kowey   PR., , Capucci   A., , Radzik   D., , Aliot   EM., , Hohnloser   SH. . Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. . N Engl J Med . 2007; ;357: : 987– 999 .
    [Google Scholar]
  6. [6]. Køber   L., , Torp-Pedersen   C., , McMurray   JJV., , Gøtzsche   O., , Lévy   S., , Crijns   H., , Amlie   J., , Carlsen   J. . Increased mortality after dronedarone therapy for severe heart failure. . N Engl J Med . 2008; ;358: : 2678– 2687 .
    [Google Scholar]
  7. [7]. Piccini   JP., , Hasselblad   V., , Peterson   ED., , Washam   JB., , Califf   RM., , Kong   DF. . Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. . J Am Coll Cardiol.   2009; ;54: : 1089– 1095 .
    [Google Scholar]
  8. [8]. Withering   W. , An account of the Foxglove and some of its medical uses: with practical remarks on dropsy, and other diseases . Birmingham: G.G.J and J. Robinson, Paternoster-Row, London   1785; .
  9. [9]. Packer   M., , Gheorghiade   M., , Young   JB., , Costantini   PJ., , Adams   KF., , Cody   RJ., , Smith   K., , Van Voorhees   L., , Gourley   LA., , Jolly   MK. . Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. . N Eng J Med . 1993; ;329: 1 : 1– 7 . doi:10.1056/NEJM199307013290101. .
    [Google Scholar]
  10. [10]. Uretsky   BF., , Young   JB., , Shahidi   FE., , Yellen   LG., , Harrison   MC., , Jolly   MK. . Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. . J Am Coll Cardiol . 1993; ;22: 4 : 955– 962 .
    [Google Scholar]
  11. [11]. The effect of digoxin on mortality and morbidity in patients with heart failure. . N Engl J Med . 1997; ;336: 8 : 525– 533 . doi:10.1056/NEJM199702203360801. .
    [Google Scholar]
  12. [12]. Freeman   JV., , Yang   J., , Sung   SH., , Hlatky   MA., , Go   AS. . Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. . Circ Cardiovasc Qual Outcomes.   2013; ;6: : 525– 533 .
    [Google Scholar]
  13. [13]. Whitbeck   MG., , Charnigo   RJ., , Khairy   P., , Ziada   K., , Bailey   AL., , Zegarra   MM., , Shah   J., , Morales   G., , Macaulay   T., , Sorrell   VL., , Campbell   CL., , Gurley   J., , Anaya   P., , Nasr   H., , Bai   R., , Di Biase   L., , Booth   DC., , Jondeau   G., , Natale   A., , Roy   D., , Smyth   S., , Moliterno   DJ., , Elayi   CS. . Increased mortality among patients taking digoxin–analysis from the AFFIRM study. . Eur Heart J [Internet] . 2013; ;34: : 1481– 1488 . Available from: http://www.ncbi.nlm.nih.gov/pubmed/23186806 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2015.4
Loading
/content/journals/10.5339/gcsp.2015.4
Loading

Data & Media loading...

  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error